In a filing, Kiniksa Pharmaceuticals Ltd revealed its CHAIRMAN & CEO Patel Sanj K unloaded Company’s shares for reported $1.37 million on Mar 07 ’24. In the deal valued at $21.02 per share,65,012 shares were sold. As a result of this transaction, Patel Sanj K now holds 0 shares worth roughly $0.0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Patel Sanj K sold 5,582 shares, generating $117,222 in total proceeds. Upon selling the shares at $21.00, the CHAIRMAN & CEO now owns 65,012 shares.
Before that, Patel Sanj K sold 12,742 shares. Kiniksa Pharmaceuticals Ltd shares valued at $273,834 were divested by the CHAIRMAN & CEO at a price of $21.49 per share. As a result of the transaction, Patel Sanj K now holds 70,594 shares, worth roughly $1.41 million.
BofA Securities reiterated its Kiniksa Pharmaceuticals Ltd [KNSA] rating to a Buy in a research note published on June 29, 2020; the price target was $40. A number of analysts have revised their coverage, including BofA/Merrill’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. Barclays began covering KNSA with “an Overweight” recommendation on March 11, 2019. Wedbush maintained its rating on December 12, 2018. It rated KNSA as “an Outperform”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals Ltd [NASDAQ:KNSA] saw its stock jump 0.05% to $19.97. Over the last five days, the stock has gained 1.37%. Kiniksa Pharmaceuticals Ltd shares have risen nearly 13.85% since the year began. Nevertheless, the stocks have risen 75.02% over the past one year. While a 52-week high of $22.09 was reached on 03/04/24, a 52-week low of $10.29 was recorded on 02/01/24. SMA at 50 days reached $19.62, while 200 days put it at $17.40. A total of 0.41 million shares were traded, compared to the trading of 0.35 million shares in the previous session.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 19.80, which if violated will result in even more drops to 19.62. On the upside, there is a resistance level at 20.20. A further resistance level may holdings at 20.42. The Relative Strength Index (RSI) on the 14-day chart is 49.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.21, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 65.40%. Stochastics %K at 34.46% indicates the stock is a holding.
How much short interest is there in Kiniksa Pharmaceuticals Ltd?
A steep rise in short interest was recorded in Kiniksa Pharmaceuticals Ltd stocks on Feb 29, 2024, growing by 20000.0 shares to a total of 2.78 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 2.76 million shares. There was a rise of 0.72%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 7.61% of the overall stock float, the days-to-cover ratio (short ratio) rose to 8.44.
The most recent change occurred on June 19, 2018 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $33 price target.
